Anaconda Biomed snares $56M in funding for endovascular tech

MedTech Anaconda Biomed snares $56M in funding for endovascular tech By Ben Adams Sep 23, 2026 3:00am blood clots Devices MedTech Medtech startup Anaconda Biomed has hauled in $53 million to help finish off work on a pivotal trial for its endovascular project. The bulk of the proceeds will go toward completing its ongoing Athena study for the ANA Funnel Catheter device, which began last April. Anaconda's device is used during stent retriever-based thrombectomy to help with clot removal in patients with large vessel occlusion acute ischemic stroke.

The rest of the cash, meanwhile, will help in the company's pursuit of product development and approvals for its neurovascular portfolio. Omega Funds led the latest round, along with new investor Spain’s Co-investment fund (FOCO, which is managed by COFIDES), with continued participation from Asabys (Sabadell Asabys II), Ysios Capital, and CDTI (through its SICC Innvierte). “This latest funding round allows us to further advance our work in the acute treatment of those suffering a stroke, with the goal of reducing disability and death caused by large vessel occlusive disease,” said Trent Reutiman, CEO of Anaconda Biomed, in a statement.

The company is also working on stent retrievers, sheaths and guidewires designed to “complement the use of the funnel catheter technology and pave the way for additional clinical applications”, it said in a release. Hatched back in 2015, Anaconda is based in Barcelona, Spain. blood clots Devices MedTech